By admin 
Missouri Attorney General Catherine Hanaway (R) has issued a stern warning to Eli Lilly and Co., demanding that the pharmaceutical giant immediately cease its practice of requiring hospitals to submit sensitive claims data as a prerequisite for receiving discounted medications under the federal 340B Drug Pricing Program. The move signals a significant escalation in the ongoing battle between state regulators and the pharmaceutical industry over the administration of a multi-billion-dollar federal safety-net program that has become a flashpoint for litigation and legislative debate.
In a formal cease-and-desist letter sent to the Indianapolis-based drugmaker on October 26, 2026, Hanaway alleged that Eli Lilly has effectively "broken" its legal and moral promise to provide affordable medicines to eligible healthcare providers in Missouri. The Attorney General’s office contends that by placing arbitrary and burdensome conditions on these discounts, the company has engaged in "false and misleading statements" regarding its compliance with federal and state obligations, potentially violating Missouri’s consumer protection and trade practice laws.
The 340B Drug Pricing Program, established by Congress in 1992, requires pharmaceutical manufacturers to provide outpatient drugs to "covered entities"—such as community health centers, children’s hospitals, and rural clinics—at significantly reduced prices. In exchange, these manufacturers are allowed to have their drugs covered by Medicaid and Medicare Part B. The program was designed to enable safety-net providers to "stretch scarce federal resources as far as possible," allowing them to provide more comprehensive services to low-income and uninsured patients. However, in recent years, the program has grown into a massive segment of the U.S. drug market, with some estimates suggesting that 340B purchases now exceed $50 billion annually.
The specific point of contention in Missouri involves Eli Lilly’s policy regarding "contract pharmacies." Because many smaller hospitals and rural clinics do not operate their own in-house pharmacies, they contract with third-party retail pharmacies (like Walgreens or CVS) to dispense medications to their patients. For years, this arrangement functioned without major friction. However, starting around 2020, Eli Lilly and several other major drugmakers began restricting 340B discounts for drugs dispensed through these contract pharmacies, unless the hospitals agreed to upload extensive, patient-level claims data to a third-party platform known as 340B ESP.
Attorney General Hanaway’s letter highlights a specific instance involving University of Missouri Health Care (MU Health Care), which operates seven hospitals across the state. According to the Attorney General, MU Health Care recently attempted to comply with Eli Lilly’s demands by agreeing to provide the requested claims data. Despite this concession, Hanaway maintains that Eli Lilly continued to deny the healthcare system the discounts to which it is legally entitled. This refusal, Hanaway argues, demonstrates that the data-sharing requirement is not a transparency measure, but rather a tactical hurdle designed to suppress the use of 340B discounts and protect corporate profit margins.
"Missouri’s healthcare providers rely on the 340B program to sustain their missions of serving our most vulnerable citizens," Hanaway wrote in the letter. "By unilaterally imposing data-sharing mandates that are not found in the federal statute, and then failing to honor discounts even when those mandates are met, Eli Lilly is jeopardizing the stability of our state’s healthcare infrastructure. This office will not stand by while a corporation prioritizes its bottom line over the health of Missourians."
The pharmaceutical industry, led by Eli Lilly and industry trade groups like PhRMA (Pharmaceutical Research and Manufacturers of America), has long argued that the 340B program has expanded far beyond its original intent. They contend that the use of contract pharmacies has led to a lack of transparency, making it difficult to track whether discounts are actually benefiting patients or simply padding the profits of large pharmacy chains and hospital systems. Furthermore, drugmakers argue that without detailed claims data, they are often forced to pay "duplicate discounts"—where they provide a 340B discount on a drug and then are also forced to pay a Medicaid rebate on the same unit of medicine, which is prohibited by federal law.
Eli Lilly has defended its data-submission policy as a necessary tool for "program integrity." The company has previously stated that the 340B ESP platform is designed to identify and prevent these duplicate discounts, ensuring that the program remains sustainable for the future. However, hospitals and safety-net advocates view the policy as a "data grab" that violates patient privacy and imposes an unmanageable administrative burden on already-strained medical staff.
The Missouri intervention is part of a broader national trend where state governments are stepping in to fill a regulatory vacuum. While the federal Health Resources and Services Administration (HRSA) oversees the 340B program, its enforcement authority has been repeatedly challenged in court. Several federal appellate courts have issued conflicting rulings on whether the 340B statute allows drugmakers to restrict the use of contract pharmacies. For instance, the Third Circuit Court of Appeals ruled in favor of drugmakers, stating the law does not explicitly prohibit them from imposing conditions on delivery to contract pharmacies. Conversely, other courts and the Department of Health and Human Services (HHS) have maintained that the discounts must be "all-inclusive" for eligible entities.
Frustrated by the slow pace of federal litigation and the perceived "toothlessness" of HRSA, states like Arkansas, Louisiana, and Minnesota have passed their own laws to protect 340B providers. These state laws generally prohibit drug manufacturers from interfering with a hospital’s choice of pharmacy. Missouri’s Attorney General appears to be following this path of state-level assertiveness, utilizing the power of the AG’s office to enforce consumer protection statutes against what she characterizes as predatory corporate behavior.
The financial stakes are immense. For Eli Lilly, the 340B program impacts some of its most profitable products, including its blockbuster insulin line and its newer, highly sought-after GLP-1 medications for diabetes and obesity, such as Mounjaro and Zepbound. As the demand for these treatments sky-rockets, the volume of 340B discounts becomes a significant factor in the company’s quarterly earnings. For Missouri hospitals, the loss of these discounts can mean the difference between maintaining a rural maternity ward or being forced to shut it down due to insolvency.
Industry analysts suggest that Hanaway’s letter could embolden other Republican Attorneys General to take similar action. While 340B is often framed as a regulatory issue, it has become a populist cause in many "red" states where rural hospitals are the largest employers and the primary source of care for aging populations. Protecting these institutions from "Big Pharma" is a political win that transcends traditional partisan lines.
Legal experts anticipate that Eli Lilly may challenge the Missouri Attorney General’s authority in federal court, arguing that federal law (the 340B statute) preempts state-level enforcement. This "preemption" argument has been the central focus of the pharmaceutical industry’s defense against state 340B laws. If Missouri proceeds with a formal lawsuit following the November 26 deadline set in the cease-and-desist letter, it could set the stage for a landmark case that determines the extent to which states can regulate the commercial conduct of drug manufacturers within their borders.
The outcome of this standoff will be closely watched by healthcare executives and pharmaceutical lobbyists nationwide. If Missouri succeeds in forcing Eli Lilly to back down, it could trigger a domino effect, leading to the dismantling of data-sharing requirements across the country and restoring the flow of discounts to thousands of contract pharmacies. If Eli Lilly prevails, it would solidify the industry’s power to set its own terms for participation in federal programs, potentially leading to further restrictions on drug access for low-income populations.
As the November 26 deadline approaches, Missouri’s healthcare community remains on high alert. For now, Hanaway has made it clear that her office views the 340B program not as a voluntary charity by drug companies, but as a mandatory condition of doing business in the state—a condition that she intends to enforce with the full weight of her office. The message to Indianapolis is clear: the era of unilateral changes to 340B access in the "Show-Me State" is over.
